Pharvaris (NASDAQ:PHVS) Director Sells 14,493 Shares of Stock

Pharvaris N.V. (NASDAQ:PHVS) Director Robert Glassman sold 14,493 shares of the company’s stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $38.56, for a total value of $558,850.08. Following the transaction, the director owned 10,500 shares of the company’s stock, valued at approximately $404,880. The trade was a 57.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Robert Glassman also recently made the following trade(s):

• On Tuesday, September 15th, Robert Glassman sold 8,667 shares of Pharvaris stock. The stock was sold at an average price of $38.27, for a total value of $331,686.09.
• On Wednesday, September 9th, Robert Glassman sold 8,000 shares of Pharvaris stock. The shares were sold at an average price of $37.55, for a total transaction of $300,400.00.

Pharvaris Stock Performance

Shares of PHVS traded down $0.35 during midday trading on Monday, hitting $36.02. 653,689 shares of the stock traded hands, compared to its average volume of 412,750. The business’s 50 day moving average price is $35.37 and its two-hundred day moving average price is $31.75. The firm has a market capitalization of $2.36 billion, a PE ratio of -11.81 and a beta of -2.33. Pharvaris N.V. has a 1-year low of $20.65 and a 1-year high of $43.25.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). As a group, equities research analysts forecast that Pharvaris N.V. will post -3.12 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on PHVS. Oppenheimer reaffirmed an “outperform” rating and set a $75.00 price target on shares of Pharvaris in a report on Tuesday, September 8th. New Street Research set a $60.00 target price on Pharvaris in a research note on Friday, August 14th. Leerink Partners increased their price target on Pharvaris from $50.00 to $65.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 9th. Royal Bank Of Canada increased their target price on shares of Pharvaris from $52.00 to $62.00 and gave the company an “outperform” rating in a research report on Wednesday, September 9th. Finally, Citigroup restated a “market outperform” rating on shares of Pharvaris in a research report on Wednesday, September 9th. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Pharvaris currently has an average rating of “Moderate Buy” and an average target price of $59.87.

Institutional Investors Weigh In On Pharvaris

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Quantbot Technologies LP bought a new position in shares of Pharvaris during the 2nd quarter valued at about $41,000. CoreCap Advisors LLC acquired a new stake in Pharvaris during the second quarter valued at approximately $93,000. Public Employees Retirement System of Ohio bought a new stake in Pharvaris during the second quarter worth approximately $196,000. Algert Global LLC acquired a new position in Pharvaris in the second quarter worth approximately $238,000. Finally, Persistent Asset Partners Ltd acquired a new position in Pharvaris in the second quarter worth approximately $273,000.

About Pharvaris

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.